eXoZymes (EXOZ) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 7.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 31
• Sector: Technology
• Sector Strength: 90
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 8,367,810
• 10 Day Avg. Volume: 6,069
• 30 Day Avg. Volume: 7,803
• PEG Ratio: 0.31
• Price to Book (P/B): 9.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -548.81
• Enterprise Value/Ebitda: -3.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

eXoZymes' financial performance is the primary concern due to zero revenue generation and continuous operational losses. The technical analysis also points to a bearish trend, with the stock trading below key moving averages. The valuation remains difficult to assess without traditional metrics. These factors contribute to a low overall stock score, indicating significant risk.

eXoZymes Business Overview & Revenue Model

Company Description

eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

How the Company Makes Money

eXoZymes generates revenue through the sale of its enzyme products to industrial clients seeking to improve their processes' efficiency and sustainability. The company operates on a B2B model, offering tailored enzyme solutions that cater to specific industrial needs. Key revenue streams include direct sales of enzyme formulations, licensing agreements for proprietary enzyme technology, and strategic partnerships with industrial enterprises aiming to integrate eco-friendly solutions into their operations. Additionally, eXoZymes may engage in research collaborations with academic institutions, receiving funding to further develop its enzyme technologies, which can contribute to its earnings.

eXoZymes Financial Statement Overview

Summary

eXoZymes faces substantial financial hurdles, primarily due to zero revenue generation and persistent operational losses. While the balance sheet shows improved equity, the reliance on external financing and negative cash flows highlight sustainability concerns. The company needs to address its revenue generation and operational efficiency to improve its financial health.

Income Statement

eXoZymes has consistently reported zero revenue over the past years, indicating a lack of revenue generation capabilities. The company is operating at a loss with a negative EBIT and net income, reflecting significant operational challenges. The absence of revenue growth further underscores the financial struggles, posing a substantial risk to future profitability.

Balance Sheet

eXoZymes exhibits a relatively strong equity position with an improvement in stockholders' equity from negative to positive in the latest year. The debt-to-equity ratio indicates manageable leverage, but the lack of revenue generation raises concerns about future sustainability. The equity ratio reflects a strong equity base but is overshadowed by the absence of revenue.

Cash Flow

The company's operating cash flow is negative, indicating challenges in covering operational expenses. However, significant financing inflows have bolstered cash reserves, suggesting reliance on external funding. The free cash flow remains negative, emphasizing difficulties in generating cash for reinvestment and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-139.38K	0.00	0.00	0.00	0.00
EBITDA	-8.52M	-5.66M	-1.60M	-1.18M	-1.23M
Net Income	-8.55M	-5.86M	-2.04M	-1.40M	-1.21M
Balance Sheet
Total Assets	11.53M	13.03M	3.56M	2.69M	2.35M
Cash, Cash Equivalents and Short-Term Investments	8.51M	9.72M	66.53K	558.57K	547.81K
Total Debt	1.33M	1.39M	1.61M	608.77K	720.63K
Total Liabilities	2.64M	2.61M	3.94M	1.31M	1.15M
Stockholders Equity	8.88M	10.42M	-384.32K	1.37M	1.20M
Cash Flow
Free Cash Flow	-10.20M	-8.90M	-1.47M	-1.44M	-2.01M
Operating Cash Flow	-9.92M	-8.51M	-1.18M	-1.26M	-1.59M
Investing Cash Flow	-247.83K	-359.22K	-311.17K	-87.21K	-312.25K
Financing Cash Flow	18.57M	18.52M	1.00M	1.36M	2.31M

eXoZymes Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$1.47B	2.06	-28.25%	3.11%	16.21%	-7.40%
BDRX	45 Neutral	$584.35K	―	-89.21%	―	-83.72%	99.56%
GRI	45 Neutral	$3.71M	―	-468.00%	―	―	98.55%
EXOZ	35 Underperform		―		―	―	―
SLRX	30 Underperform	$1.66M	―	-300.16%	―	―	79.57%
PCSA	29 Underperform	$6.02M	―	-192.72%	―	―	56.26%
PTIX	27 Underperform	$3.20M	―	-512.79%	―	―	-40.51%

eXoZymes Corporate Events

eXoZymes Announces Leadership Changes with New Appointments

On February 17, 2025, eXoZymes Inc., a Nevada corporation, experienced significant leadership changes as Mr. Mohammad Hayat resigned from his roles as President, Chairman, and Board member. Subsequently, the Board appointed Mr. Edgardo Rayo as a new Board member and Mr. Christopher A. Marlett as the new Chairman.